Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months

This study demonstrates that treatment with olipudase alfa for 30 months is well-tolerated and associated with life-transforming sustained improvem ents in relevant disease clinical measures.
Source: Journal of Inherited Metabolic Disease - Category: Internal Medicine Source Type: research